|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Role of p63 and p73 isoforms on the cell death in patients with hepatocellular carcinoma submitted to orthotopic liver transplantation.
|
28350813 |
2017 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results demonstrated the in vitro and in vivo anti-tumor potential of PBLs, supporting their application as a novel chemopreventive agent for the treatment of human hepatocellular carcinoma (HCC) in the future via targeting the p73 pathway.
|
25371988 |
2014 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Doxorubicin strongly induces p53 and p73 binding to the NIS promoter, leading to an increased expression of endogenous NIS mRNA and protein in HCC and CCA cells, but not in PHH.
|
24052075 |
2013 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that the p73 G4C14-to-A4T14 dinucleotide polymorphism may play a role in the development of chronic HBV-infected HCC in the Chinese population, especially among women.
|
23065572 |
2013 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We compared p53 and p73 interactions with HBx in normal and HCC tumor cell lines differing in their p53 status.
|
22030623 |
2011 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-tumoral effects of nutlin-3 targeting the p53 and p73 pathways were evaluated in HCC cell lines.
|
21261729 |
2011 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We investigated the molecular mechanisms of mutant p53 gain-of-function in hepatocellular carcinoma with special emphasis on the interaction of mutant p53 gain-of-function proteins with the p53 family members p63 and p73.
|
20233581 |
2010 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We used human normal and diseased liver tissue samples, as well as human HCC cell lines, to examine the association between activation of epidermal growth factor receptor (EGFR) by its ligand amphiregulin (AR) and the alternative splicing of p73 pre-mRNA into the tumorigenic isoform DeltaEx2p73, via c-Jun N-terminal-kinase-1-mediated signaling.
|
19664633 |
2009 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent findings demonstrating p73 and specifically N-terminally truncated p73 (DeltaTAp73) accumulation in hepatocellular carcinoma suggest that p73 plays a role in the malignant phenotype.
|
18342333 |
2008 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We investigated allelic status of p73 in 63 patients with HCC.
|
14719122 |
2004 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Although we only analyzed 10 patient samples the results strongly suggest that the elevated activity of the first promoter (TA promoter) accounts for high-level expression of both full-length TA-p73 and aberrantly spliced DeltaTA-p73 isoforms in hepatocellular carcinoma tissues.
|
14760085 |
2004 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
We investigated allelic status of p73 in 63 patients with HCC.
|
14719122 |
2004 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The p73 mRNA and protein were highly expressed and accumulated in HCC tissues.
|
11991598 |
2002 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results do not support p73 as a tumor suppressor in HCC, but suggest that overexpression of p73 may in some way be associated with the pathogenesis of HCC.
|
12546528 |
2002 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Unlike p53, p73 deficiency in mice does not lead to a cancer-prone phenotype, and p73 gene is not mutated in human cancers, including hepatocellular carcinoma.
|
11526499 |
2001 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that p73 is a biallelically expressed gene in the liver and that allelic loss and mutation of p73 is infrequent and may occur early in HCC. p73 is unlikely to be the putative tumor suppressor gene located at chromosome 1p36 in HCC.
|
10928060 |
2000 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
No p73 protein expression was observed by immunohistochemistry in nonmalignant liver tissue or in HCC. p53 inactivation appeared to be associated with up-regulation of p73 expression, suggesting a compensatory role for p73 in this situation.
|
10706549 |
2000 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The frequency of p73 loss of heterozygosity was observed in 20% of HCCs, but PCR-single strand conformation polymorphism (SSCP) analysis showed no mutations in the 48 tumours except for three types of polymorphisms.
|
10408709 |
1999 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In situ hybridization and immunohistochemistry for the detection of p73 RNA transcripts and protein, respectively, were performed in tissues from 193 patients with curatively (R0-) resected HCC.
|
10393724 |
1999 |